2X Blend: CJC-1295 / Ipamorelin

Components: CJC-1295 (Modified GRF 1-29, typically without DAC) + Ipamorelin Typical Ratio: 1:1 or 1:2 (CJC:Ipamorelin) Common Formulation: 200 mcg CJC-1295 + 200 mcg Ipamorelin per dose Classification: Growth Hormone Secretagogue (GHS) Combination

Executive Summary

The CJC-1295/Ipamorelin combination represents a synergistic growth hormone secretagogue (GHS) protocol designed to stimulate endogenous growth hormone (GH) release through complementary mechanisms: CJC-1295 (a long-acting GHRH analog) amplifies GH pulse frequency and duration, while Ipamorelin (a selective ghrelin mimetic) increases GH pulse amplitude without stimulating cortisol or ACTH. This "2X Blend" gained popularity in anti-aging, bodybuilding, and regenerative medicine communities for purported benefits including increased lean muscle mass, accelerated fat loss, improved sleep quality, enhanced recovery, and skin/connective tissue rejuvenation.

Mechanistically, CJC-1295 (Mod GRF 1-29, typically without DAC in combination protocols) is a 30-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) with amino acid substitutions conferring resistance to dipeptidyl peptidase-4 (DPP-4) degradation. This extends its half-life from minutes (native GHRH) to approximately 30 minutes to 2 hours when unmodified, or 6-8 days when conjugated with Drug Affinity Complex (DAC), which binds serum albumin. CJC-1295 signals through the GHRH receptor (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase/cAMP/PKA pathways to promote GH synthesis and pulsatile secretion.

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂, 711.85 Da) derived from GHRP-1, functioning as a highly selective growth hormone secretagogue receptor (GHSR-1a, ghrelin receptor) agonist. Unlike earlier GHRPs (GHRP-2, GHRP-6, hexarelin), ipamorelin demonstrates remarkable selectivity: it stimulates GH release without concomitant ACTH, cortisol, or prolactin elevation, even at doses 200-fold above the ED50 for GH release. This selectivity profile resembles GHRH itself, minimizing hypothalamic-pituitary-adrenal (HPA) axis disruption and side effects associated with non-selective GHRPs.

When combined, CJC-1295 and Ipamorelin exhibit synergistic pharmacodynamics: CJC-1295 provides sustained GHRH receptor stimulation (increasing GH pulse frequency and baseline secretion), while Ipamorelin delivers acute ghrelin receptor activation (amplifying individual GH pulse amplitude). Clinical observations suggest this combination can double serum IGF-1 levels compared to ipamorelin monotherapy, with GH elevations sustained for extended periods due to CJC-1295's pharmacokinetic profile. After a single CJC-1295 injection, plasma GH concentrations increase 2-10-fold for ≥6 days, and IGF-1 levels rise 1.5-3-fold for 9-11 days; with repeated dosing, IGF-1 elevation persists up to 28 days.

Despite promising pharmacology and widespread off-label use, both peptides remain unapproved by the FDA for any therapeutic indication. CJC-1295 advanced to Phase II clinical trials for lipodystrophy and growth hormone deficiency but was discontinued following the death of a trial participant (causality uncertain). The FDA subsequently terminated further research as a precautionary measure. In December 2024, the FDA issued warnings regarding compounded CJC-1295 and Ipamorelin, specifically citing serious adverse events including death (IV Ipamorelin administration), cardiac events (CJC-1295), immunogenicity risks, and concerns over peptide impurities in compounded preparations.

Standard dosing protocols employ subcutaneous injection of 100-300 mcg CJC-1295 + 100-300 mcg Ipamorelin, typically administered before bed on an empty stomach. A common regimen is 200 mcg of each peptide daily or via a "5-on-2-off" schedule (5 consecutive days, 2 days rest) to maintain pituitary sensitivity. Cycles typically span 12 weeks followed by 4-week breaks. Safety profiles from clinical trials show generally well-tolerated effects at therapeutic doses, with common adverse events limited to injection site reactions, transient headaches, and mild flu-like symptoms. However, FDA warnings emphasize risks including carpal tunnel syndrome, blood sugar dysregulation, and potential immunogenicity, particularly with long-term or high-dose use.

Goal Relevance:

• Enhance muscle growth and strength for bodybuilding or athletic performance.
• Support fat loss and improve body composition for weight management.
• Improve sleep quality and promote deeper, more restorative sleep.
• Aid in recovery and healing from injuries or intense physical activity.
• Boost energy levels and overall vitality for anti-aging purposes.
• Rejuvenate skin and connective tissue for a more youthful appearance.
• Optimize hormone levels to support overall well-being and energy.
• Increase lean muscle mass while minimizing unwanted side effects like cortisol elevation.

Chemical Structure & Composition

CJC-1295 (Modified GRF 1-29)

Full Sequence (30 amino acids): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Molecular Characteristics:

• Molecular Weight: 3,367.95 g/mol (without DAC); 3,647.95 g/mol (with DAC)
• Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆ (approximate, without DAC)
• Modifications vs Native GHRH:
  • Position 2: D-Alanine (D-Ala) replaces L-alanine → Confers DPP-4 resistance
  • Position 8: Glutamine (Gln) substitution → Enhanced receptor binding
  • Position 15: Alanine (Ala) substitution → Improved stability
  • Position 27: Leucine (Leu) alteration → Optimized bioactivity

DAC (Drug Affinity Complex) Modification:

• Chemical structure: Nɛ-maleimidopropionyl-Lysine attached to C-terminus
• Function: Covalently binds serum albumin (half-life extension mechanism)
• Molecular weight addition: +280 Da
• Pharmacokinetic impact: Half-life extended from 30 min-2 hr → 6-8 days

Critical Nomenclature:

• CJC-1295 WITHOUT DAC = Modified GRF (1-29) = Tesamorelin analog (most common in blends)
• CJC-1295 WITH DAC = Albumin-binding long-acting variant (less common in combinations due to sustained GH elevation concerns)

For combination protocols with Ipamorelin, CJC-1295 WITHOUT DAC is typically used to allow pulsatile GH release patterns mimicking physiological secretion, rather than sustained supra-physiological elevation.

Ipamorelin

Sequence (Pentapeptide): Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Where:

• Aib = α-aminoisobutyric acid (non-proteinogenic amino acid)
• D-2-Nal = D-2-naphthylalanine (aromatic, bulky side chain)
• D-Phe = D-phenylalanine (D-amino acid for peptidase resistance)

Molecular Characteristics:

• Molecular Weight: 711.85 Da (0.71 kDa)
• Molecular Formula: C₃₈H₄₉N₉O₅
• C-terminal amidation (-NH₂): Critical for receptor binding and bioactivity
• Non-proteinogenic residues: Aib and D-2-Nal confer resistance to enzymatic degradation

Structural Derivation:

• Parent peptide: GHRP-1 (Growth Hormone-Releasing Peptide-1)
• Modification: Ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of GHRP-1
• Result: Enhanced selectivity for GH release; elimination of ACTH/cortisol stimulation

Receptor Selectivity:

• Target: Growth hormone secretagogue receptor 1a (GHSR-1a, ghrelin receptor)
• Binding affinity: Nanomolar range (EC50 for GH release ~214 nM in humans)
• Selectivity index: >200-fold selectivity for GH vs ACTH release (first selective GHRP)

Combination Formulation (2X Blend)

Typical Compounded Ratios:

• 1:1 ratio: 5 mg CJC-1295 + 5 mg Ipamorelin per vial (total 10 mg)
• 1:2 ratio: 5 mg CJC-1295 + 10 mg Ipamorelin per vial (total 15 mg)

Reconstitution:

• Diluent: Bacteriostatic water (0.9% benzyl alcohol) or sterile water
• Typical concentration: 200 mcg/0.2 mL per component (for 200 mcg doses)
• Final volume: 2-5 mL per vial depending on formulation

Stability Considerations:

• Lyophilized (freeze-dried): Stable 12-24 months at 2-8°C
• Reconstituted: Stable 7-14 days refrigerated (bacteriostatic water), 3-5 days (sterile water)
• Freeze-thaw cycles: Avoid; causes aggregation and potency loss

Mechanism of Action

CJC-1295: GHRH Receptor Agonism

Primary Mechanism:

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to mimic GHRH and signal the pituitary gland to release growth hormone. It binds to and activates the GHRH receptor (GHRHR), a class B G protein-coupled receptor (GPCR) expressed on anterior pituitary somatotrophs.

Intracellular Signaling Cascade:

1. GHRHR activation → Gαs protein coupling
2. Adenylyl cyclase stimulation → cAMP production ↑↑
3. Protein kinase A (PKA) activation → CREB phosphorylation
4. CREB-mediated transcription → GH gene expression ↑
5. Calcium mobilization → Vesicular GH exocytosis from somatotrophs

Pharmacological Outcomes:

• Increased GH pulse frequency: More frequent secretory bursts throughout 24-hour period
• Elevated baseline GH: Sustained mild elevation in trough GH levels
• Prolonged secretory duration: Extended GH secretory episodes (6+ days with single dose)

Resistance to Degradation: Native GHRH is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) at the Ala2-Asp3 bond, yielding a half-life of <7 minutes. CJC-1295 incorporates D-Ala2 (D-amino acid substitution), rendering the peptide DPP-4-resistant and extending half-life dramatically.

IGF-1 Stimulation: GH released from the pituitary travels to the liver, stimulating insulin-like growth factor 1 (IGF-1) production via the GH receptor (GHR) → JAK2/STAT5 signaling. IGF-1 mediates most anabolic effects attributed to GH (muscle protein synthesis, lipolysis, connective tissue growth).

Ipamorelin: Ghrelin Receptor Agonism

Primary Mechanism:

Ipamorelin is a ghrelin mimetic that binds to the growth hormone secretagogue receptor 1a (GHSR-1a), also known as the ghrelin receptor, expressed on pituitary somatotrophs and hypothalamic arcuate nucleus neurons.

Receptor Activation:

1. GHSR-1a binding → Gαq protein coupling (distinct from GHRHR's Gαs)
2. Phospholipase C (PLC) activation → IP₃ and DAG generation
3. Intracellular Ca²⁺ release → Rapid GH vesicle exocytosis
4. MAPK/ERK pathway activation → GH gene transcription (sustained effect)

Pharmacological Outcomes:

• Amplified GH pulse amplitude: Larger individual secretory bursts (peak GH concentration ↑)
• Rapid onset: GH peak at 0.67 hours (40 minutes) post-injection
• Short duration: Exponential decline to negligible levels within 4-6 hours
• Selective GH release: NO ACTH, cortisol, or prolactin stimulation (unique among GHRPs)

Mechanism of Selectivity:

Ipamorelin's selectivity arises from its structural specificity for GHSR-1a. Unlike GHRP-2 or GHRP-6, which also activate melanocortin receptors (MC3R/MC4R) and trigger hypothalamic CRH/ACTH cascades, ipamorelin exhibits >200-fold selectivity for GH release over ACTH secretion. Even at doses vastly exceeding the ED50 for GH release, ipamorelin did not release ACTH or cortisol in levels significantly different from GHRH stimulation alone.

Synergistic Combination Effects

Complementary Pathways:

CJC-1295 and ipamorelin work through distinct receptors and intracellular pathways:

• CJC-1295: GHRHR → Gαs → cAMP/PKA → Sustained GH gene transcription + moderate GH secretion
• Ipamorelin: GHSR-1a → Gαq → PLC/Ca²⁺ → Rapid GH vesicle release

Synergistic Amplification:

When paired with a GHRP like Ipamorelin, CJC-1295 amplifies the growth hormone pulse amplitude and frequency, creating a synergistic effect greater than either peptide alone. Mechanistically:

1. CJC-1295 priming: Upregulates GH synthesis and vesicle stores in somatotrophs
2. Ipamorelin triggering: Acute Ca²⁺ mobilization releases accumulated GH stores
3. Result: Higher peak GH concentrations from ipamorelin's pulse + sustained elevation from CJC-1295

Clinical Evidence:

Research shows that combining Ipamorelin with CJC-1295 can double IGF-1 levels compared to using Ipamorelin alone. This IGF-1 doubling effect reflects enhanced hepatic GH receptor stimulation due to synergistic GH release.

Pulsatile vs Sustained Release:

By combining CJC-1295's long-acting GH pulse frequency stimulation with Ipamorelin's clean, selective GH amplitude increase, this stack mimics the body's natural growth hormone secretion patterns, avoiding the supra-physiological continuous elevation seen with GH injections or long-acting analogs alone.

Goal Archetype Integration

The CJC-1295/Ipamorelin blend represents the "gold standard" GH peptide stack due to its synergistic mechanism targeting both GHRH and ghrelin receptor pathways simultaneously. This dual-pathway activation makes it the most versatile GH secretagogue combination for multiple optimization goals.

Primary Goal Alignment

Why This Blend is the "Gold Standard"

Mechanistic Synergy: The CJC-1295/Ipamorelin combination achieves true pharmacological synergy because each peptide targets a distinct receptor and signaling pathway:

Combined Effect: When both pathways converge simultaneously:

1. CJC-1295 upregulates GH synthesis and "loads" the secretory vesicles
2. Ipamorelin triggers Ca2+ mobilization that "releases" the accumulated stores
3. Result: GH pulse amplitude 2-3x greater than either peptide alone (true synergy, not additive)

Selectivity Advantage: Unlike earlier GHRPs (GHRP-2, GHRP-6), this combination maintains exceptional selectivity:

• NO cortisol elevation (avoids catabolic effects that oppose GH's anabolic action)
• NO prolactin stimulation (avoids side effects like gynecomastia, libido changes)
• Minimal appetite stimulation (unlike GHRP-6's pronounced hunger effects)

When This Blend Makes Sense

Ideal Candidates:

1. Adults with age-related GH decline (Somatopause)

   • Progressive decline in GH secretion (14% per decade after age 30)
   • Symptoms: fatigue, poor recovery, increased body fat, reduced lean mass, sleep disturbance
   • Low-normal IGF-1 levels on baseline testing
   • Synergistic combination compensates for reduced pituitary responsiveness

2. Recovery-focused individuals

   • Athletes in intensive training blocks requiring enhanced recovery
   • Post-injury or post-surgical healing (off-label)
   • Those experiencing prolonged DOMS (delayed onset muscle soreness)
   • Collagen/connective tissue repair needs (tendons, ligaments)

3. Body recomposition goals

   • Simultaneous fat loss and lean mass preservation/gain
   • Particularly effective for visceral adipose tissue reduction
   • Best results when combined with resistance training and appropriate nutrition

4. Anti-aging and longevity optimization

   • Comprehensive GH axis restoration
   • Skin, bone, and cognitive health maintenance
   • Sleep quality improvement
   • Metabolic health support

5. Those who failed single-peptide therapy

   • Inadequate IGF-1 response to ipamorelin alone
   • Looking for enhanced efficacy without supraphysiological dosing

When to Choose Something Else

Consider alternatives when:

1. Budget constraints

   • Single peptide (ipamorelin alone) more affordable
   • May achieve 60-70% of combination benefit at lower cost

2. Simplicity preferred

   • New to peptides; start with single compound to assess tolerance
   • Add second peptide in subsequent cycle if needed

3. Sustained GH elevation needed (rare)

   • CJC-1295 WITH DAC provides continuous (non-pulsatile) elevation
   • Appropriate for certain clinical scenarios requiring steady-state GH
   • Generally NOT recommended for optimization protocols

4. Specific contraindications apply

   • Active cancer or history of cancer (GH/IGF-1 mitogenic)
   • Critical illness
   • Pregnancy/breastfeeding
   • Competitive athletes under WADA testing

5. GHRH-only stimulation desired

   • Tesamorelin (FDA-approved for HIV lipodystrophy) may be appropriate
   • Provides GHRH pathway stimulation without ghrelin pathway

Age-Stratified Dosing (Combined Blend)

Age significantly impacts GH axis function, pituitary responsiveness, and risk profile. The following age-stratified recommendations provide combined dosing guidance for the CJC-1295/Ipamorelin blend.

Dosing Rationale by Age

Why age matters:

• Younger adults (<40): Robust pituitary function; lower doses often sufficient
• Middle age (40-55): Progressive somatopause onset; moderate dose escalation compensates
• Older adults (55+): Significant GH decline but increased comorbidity risk; conservative approach with enhanced monitoring

Under 40 Years: Conservative Protocol

Rationale:

• Pituitary highly responsive at this age; lower doses sufficient
• Focus on amplifying natural GH pulse rather than replacing
• Conservative approach minimizes risk while achieving benefits
• Twice daily dosing rarely necessary unless aggressive performance goals

Special Considerations:

• If IGF-1 response inadequate at 6-8 weeks, consider titrating to optimal dose
• May use twice daily (AM + PM) for intensive recovery periods
• Lifestyle optimization (sleep, training, nutrition) should be foundational

Ages 40-55 Years: Standard Protocol

Rationale:

• Moderate dose escalation compensates for declining pituitary responsiveness
• Standard combination ratio (CJC-1295:Ipamorelin approximately 1:1.5 to 1:2)
• Twice daily option for body composition or enhanced recovery goals
• Represents most common dosing range in clinical anti-aging practice

Special Considerations:

• Monitor metabolic markers more closely (emerging insulin resistance risk)
• Consider thyroid function monitoring (GH affects T4 to T3 conversion)
• Titrate based on IGF-1 response and subjective benefits

Ages 55+ Years: Conservative Protocol with Enhanced Monitoring

Rationale:

• Start conservative; older pituitary may require time to respond
• Increased sensitivity to both benefits AND side effects
• Higher prevalence of comorbidities requires careful monitoring
• Quality of life and safety paramount over aggressive optimization

Special Considerations:

• More frequent glucose monitoring (increased insulin resistance risk with age)
• Cancer screening should be current before initiating
• Cardiovascular assessment recommended
• May require 12+ weeks to see full benefits (slower tissue response)
• Consider longer off-cycle periods (6-8 weeks vs standard 4 weeks)
• IGF-1 ceiling of <400 ng/mL especially important for cancer risk management

Age-Stratified Quick Reference Table

Sex-Specific Considerations

Males:

• Standard dosing applies as outlined above
• Monitor for excessive IGF-1 elevation (prostatic concerns with sustained high IGF-1)
• PSA monitoring recommended for males 50+
• Synergizes well with TRT if appropriate

Females:

• Generally start at lower end of dose ranges (more sensitive to GH effects)
• Water retention may be more pronounced; monitor and adjust
• Hormonal Cycle Considerations:
  • Some practitioners prefer consistent daily dosing regardless of cycle phase
  • Others suggest slightly higher doses during luteal phase when natural GH may be lower
  • Avoid initiation during perimenopause hormonal fluctuations if possible
• Oral estrogen reduces IGF-1 response (consider transdermal estrogen if on HRT)
• Monitor thyroid function closely (women more susceptible to thyroid changes)

Drug Interactions - Comprehensive

Prescription Medications

Other Peptides/Compounds (Stacking)

Supplements

Foods/Timing Interactions

Drug Interaction Summary

Bloodwork Impact & Monitoring

Expected Marker Changes

Target IGF-1 Ranges

Goal: Age-Appropriate Upper Tertile with Absolute Ceiling of <400 ng/mL

Critical Safety Ceiling:

• NEVER exceed 400 ng/mL regardless of age
• Epidemiological data links sustained high IGF-1 (>400 ng/mL) to increased cancer risk
• If IGF-1 exceeds 400 ng/mL, reduce dose or discontinue
• Recheck IGF-1 4-6 weeks after dose adjustment

Monitoring Schedule

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers:

Adjustment by Response Markers:

Protocol Integration

The "Gold Standard" GH Stack: Why This Combination Works

The CJC-1295/Ipamorelin blend has earned its reputation as the gold standard GH peptide stack for several key reasons:

1. Dual Pathway Synergy (Not Additive)

• True pharmacological synergy: combined effect exceeds sum of individual effects
• GHRH pathway (CJC-1295) + Ghrelin pathway (Ipamorelin) converge on somatotrophs
• Research shows combination can double IGF-1 levels compared to ipamorelin alone

2. Preserved Physiological Pulsatility

• Both peptides are short-acting (CJC-1295 no DAC: 30 min; Ipamorelin: 2 hr)
• Combined use mimics natural GH secretion pattern
• Avoids sustained supraphysiological elevation (unlike GH injections or DAC variant)

3. Selectivity Maintained

• Ipamorelin's exceptional selectivity preserved in combination
• No cortisol elevation (avoids catabolic antagonism)
• No prolactin stimulation (avoids related side effects)
• No significant appetite stimulation

4. Single Injection Convenience

• Both peptides can be mixed in same syringe
• Complementary pharmacokinetics allow synchronized dosing
• No complex timing protocols required

Blend Advantages Over Individual Peptides

Stacking with Other Compounds

Synergistic Stacks

Stacks to Avoid

Timing Protocols

Standard Protocol (Once Daily)

Rationale: Aligns with natural nocturnal GH surge; maximizes sleep-related benefits; most convenient.

Advanced Protocol (Twice Daily)

Rationale: Mimics natural biphasic GH secretion (morning + nocturnal peaks); maximizes GH exposure for body composition/recovery goals. Reserve for experienced users with aggressive targets.

Post-Workout Protocol (Recovery Focus)

Rationale: Capitalizes on post-exercise anabolic window; GH pulse during recovery period. Requires careful meal timing around training.

Integration with Lifestyle Pillars

Cycling Recommendations

Standard Cycle:

• On-cycle: 8-12 weeks
• Off-cycle: 4 weeks
• Annual: 3 cycles per year (36 weeks on, 12 weeks off)

Rationale: Cycling prevents receptor desensitization and allows pituitary "rest." Off-cycle period maintains long-term responsiveness.

Alternative Continuous Protocol:

• Some practitioners use continuous therapy with dose adjustments
• Monitor IGF-1 every 8-12 weeks
• If IGF-1 plateaus or declines, take break
• Generally NOT recommended for long-term use without breaks

Pharmacokinetics and Metabolism

CJC-1295 Pharmacokinetics

Absorption (Subcutaneous):

• Bioavailability: High (>80% estimated based on dose-proportional PK)
• Tmax (Time to peak plasma): 1-2 hours
• Dose-dependent PK: Linear pharmacokinetics across 30-100 mcg/kg dose range

Distribution:

• Volume of distribution (Vd): Moderate (estimated 0.3-0.5 L/kg)
• Protein binding: Low for unmodified CJC; >99% albumin-bound for DAC-conjugated variant
• Tissue distribution: Limited; primarily extracellular fluid and pituitary targeting

Metabolism:

• Primary pathway: Proteolytic degradation by tissue peptidases
• DPP-4 resistance: D-Ala2 substitution confers resistance to DPP-4 cleavage (major degradation pathway for native GHRH)
• Secondary degradation: Aminopeptidases, endopeptidases, carboxypeptidases
• No CYP450 metabolism: Peptide degradation independent of hepatic cytochrome P450 enzymes

Elimination:

• Half-life (without DAC): 30 minutes to 2 hours
• Half-life (with DAC): 6-8 days (albumin-binding extends circulation time dramatically)
• Clearance: Renal and proteolytic; intact peptide minimally excreted
• Pharmacodynamic duration: GH elevation persists 6+ days after single injection (DAC variant); 6-24 hours (no DAC variant)

Dose-Response Relationship:

After a single injection of CJC-1295, there were dose-dependent increases in:

• Mean plasma GH: 2-10-fold increase sustained for ≥6 days
• Mean plasma IGF-1: 1.5-3-fold increase sustained for 9-11 days
• With multiple doses: IGF-1 levels remained elevated for up to 28 days

Ipamorelin Pharmacokinetics

Absorption (Subcutaneous/Intravenous):

• Bioavailability (SC): Estimated 50-70% (reduced vs IV due to first-pass peptidase degradation)
• Tmax: 20-40 minutes (subcutaneous); immediate (intravenous)
• Dose-proportional PK: Linear across 4.21-140.45 nmol/kg dose range

Distribution:

• Volume of distribution (Vss): 0.22 L/kg (suggests limited extravascular distribution)
• Protein binding: Minimal (<10%)
• Tissue distribution: Primarily plasma and extracellular compartments; rapid pituitary uptake

Metabolism:

• Enzymatic degradation: Peptidases (aminopeptidases, endopeptidases)
• C-terminal amidation: Protects against carboxypeptidase degradation
• D-amino acids (D-2-Nal, D-Phe): Confer resistance to stereospecific peptidases

Elimination:

• Half-life: ~2 hours (short elimination half-life)
• Clearance: 0.078 L/h/kg (moderate hepatic and renal clearance)
• Excretion: Predominantly renal (metabolites); minimal intact peptide in urine

Pharmacodynamic Time Course:

The time course of GH stimulation shows a single episode of GH release with:

• Peak GH: 0.67 hours (40 minutes) post-administration
• Duration: Exponential decline to negligible GH concentration by 4-6 hours
• Selectivity: No ACTH, cortisol, prolactin, FSH, or LH elevation at any time point

Combined PK/PD Profile

Synergistic Pharmacodynamics:

When administered together:

1. Ipamorelin: Delivers rapid GH spike (peak at 40 minutes), declines by 4-6 hours
2. CJC-1295 (no DAC): Sustains GH pulses for 6-24 hours, maintains elevated baseline
3. Result: Pulsatile GH release with amplified peaks + extended secretory window

Clinical Protocol Implications:

The short half-life of ipamorelin (2 hr) and moderate half-life of CJC-1295 no DAC (30 min-2 hr) necessitate daily or twice-daily dosing to maintain consistent GH stimulation. Clinicians often stack ipamorelin with CJC-1295 because ipamorelin delivers a rapid two-hour GH spike while CJC-1295 extends growth-hormone pulses for roughly 6-8 days (DAC variant) or sustains moderate elevation for 6-24 hours (no DAC variant).

A typical protocol mixes 100 µg CJC-1295 with 200 µg ipamorelin in one nightly subcutaneous injection to align with nocturnal GH surge (highest physiological GH secretion occurs during deep sleep stages 3-4).

Dosing Protocols and Administration

Standard Combination Dosing

Beginner Protocol:

• CJC-1295 (no DAC): 100 mcg before bed
• Ipamorelin: 100 mcg before bed
• Frequency: Once daily, 5 days per week (5-on-2-off schedule)
• Duration: 12 weeks, followed by 4-week break

Intermediate/Optimal Protocol:

• CJC-1295 (no DAC): 200 mcg before bed
• Ipamorelin: 200 mcg before bed
• Frequency: Once daily, 5-7 days per week
• Rationale: The 200 mcg combination represents optimal dosing for most individuals seeking comprehensive benefits including improved body composition, enhanced recovery, and anti-aging effects. Clinical protocols show 200 mcg of each peptide provides effective GH stimulation with minimal side effects.

Advanced Protocol:

• CJC-1295 (no DAC): 250-300 mcg before bed
• Ipamorelin: 300 mcg before bed
• Frequency: Once daily, 5 days per week
• Note: For optimum results, Ipamorelin CJC 1295 ideal dosage for bodybuilding is 300 mcg (ipamorelin) and 250 mcg (CJC 1295) per day. Higher doses increase side effect risk.

Administration Timing

Optimal Timing: It is advised to deliver Ipamorelin CJC 1295 injections on an empty stomach or at least 30 minutes after a meal. Consistent bedtime administration provides optimal results by working with natural circadian rhythms and the physiological nocturnal GH surge.

Circadian Rationale:

• Endogenous GH secretion peaks: During slow-wave sleep (stages 3-4), typically 1-3 hours after sleep onset
• Nighttime dosing synergy: Exogenous GHS administration augments the natural nocturnal pulse
• Daytime dosing: May be used for multiple daily injections (2-3x/day protocols), though less common

Frequency and Cycling

5-On-2-Off Protocol:

• Rationale: The 5-on-2-off protocol maintains pituitary sensitivity and effectiveness by preventing receptor downregulation
• Schedule: Administer Monday-Friday, rest Saturday-Sunday
• Benefit: Preserves GHRH receptor and ghrelin receptor responsiveness long-term

Continuous Daily Dosing:

• Alternative: 7 days per week for 12 weeks
• Risk: Potential receptor desensitization with prolonged continuous stimulation
• Mitigation: Lower doses (100-200 mcg range) reduce desensitization risk

Cycling Duration:

• Active phase: 12 weeks (recommended standard cycle)
• Rest phase: 4 weeks off to restore endogenous GH pulsatility and receptor sensitivity
• Long-term use: Repeat 12-week cycles indefinitely with 4-week breaks

Injection Technique

Route of Administration:

• Subcutaneous (SC) injection: Preferred route for both peptides
• Sites: Abdomen (2 inches from umbilicus), anterior thigh, upper arm
• Needle: 29-31G insulin syringe, 0.5-1 inch length
• Volume per injection: Typically 0.2-0.5 mL (depending on concentration)

Step-by-Step Administration:

1. Reconstitution:
   • Add bacteriostatic water to lyophilized vial
   • Swirl gently (do not shake vigorously)
   • Allow to dissolve completely (5-10 minutes)
2. Preparation:
   • Wash hands thoroughly
   • Clean injection site with alcohol swab
   • Draw prescribed dose into insulin syringe
3. Injection:
   • Pinch skin fold gently
   • Insert needle at 45-90° angle
   • Aspirate gently (if blood appears, withdraw and reposition)
   • Inject slowly over 5-10 seconds
   • Withdraw needle and apply gentle pressure
4. Post-injection:
   • Dispose of sharps in biohazard container
   • Refrigerate reconstituted vial (2-8°C)
   • Rotate injection sites to prevent lipohypertrophy

Special Population Dosing

Elderly (>65 years):

• Starting dose: 50-100 mcg each peptide
• Titration: Increase slowly based on tolerance
• Rationale: Age-related decline in GH responsiveness may require individualized dosing

Bodybuilding/Performance Enhancement:

• Typical dose: 200-300 mcg each peptide
• Frequency: Daily or twice daily (morning fasted + pre-bed)
• Cycle: 16-20 weeks with 8-week breaks

Anti-Aging/Longevity:

• Dose: 100-200 mcg each peptide
• Frequency: 5-on-2-off schedule
• Duration: Long-term with 4-week breaks every 12 weeks

Weight Loss/Body Recomposition:

• Dose: 200 mcg each peptide
• Frequency: Daily before bed
• Adjuncts: Combine with caloric deficit, resistance training

Monitoring and Titration

Baseline Assessment:

• Serum IGF-1: Establish baseline before initiating therapy
• Fasting glucose, HbA1c: Screen for insulin resistance
• Lipid panel: Assess cardiovascular risk
• Thyroid function (TSH, free T4): GH affects thyroid metabolism

On-Treatment Monitoring:

• IGF-1 levels: Every 4-8 weeks; target physiological range (250-350 ng/mL for adults)
• Fasting glucose: Every 8-12 weeks (GH can impair insulin sensitivity)
• Clinical symptoms: Sleep quality, body composition changes, joint pain, edema
• Side effects: Injection site reactions, carpal tunnel symptoms, headaches

Dose Titration:

• Upward titration: Increase by 50-100 mcg increments if IGF-1 remains low (<200 ng/mL) and tolerance is good
• Downward titration: Reduce dose if IGF-1 exceeds 400 ng/mL or side effects emerge
• Individual variability: Response varies based on age, body composition, baseline GH status

Clinical Research & Evidence

CJC-1295 Clinical Trials

Phase I Safety and Pharmacokinetics:

CJC-1295 was administered subcutaneously in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study. The peptide was safe and relatively well tolerated, particularly at doses of 30 or 60 micrograms/kg. Some studies have calculated the dose at 1-2 mcg per kg body weight.

Phase II Efficacy Trials:

After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 days with no serious adverse reactions reported. At 100 microg/kg, adverse reactions (mainly gastrointestinal) proved more frequent, though no serious adverse events were recorded.

Lipodystrophy and Growth Hormone Deficiency:

CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency and reached phase II clinical trials. However, development was discontinued upon the death of one of the trial subjects, and research was terminated as a precaution. The relationship between CJC-1295 administration and the death was never conclusively established, but regulatory caution halted further trials.

Animal Models:

Once-daily administration of CJC-1295 in growth hormone-releasing hormone (GHRH) knockout mice normalized growth, demonstrating biological efficacy in GH-deficient models. This supports the peptide's mechanism as a functional GHRH analog capable of restoring GH axis function.

Ipamorelin Clinical Trials

Phase I/II Pharmacokinetic-Pharmacodynamic Studies:

A clinical trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.

Key Findings:

• GH Stimulation: Ipamorelin induces release of GH at all dose levels
• EC50: Concentration required for half-maximal GH stimulation of 214 nmol/L
• Maximal GH production rate: 694 mIU/L/h
• Selectivity: Ipamorelin significantly and selectively increased plasma GH levels without any change in prolactin, FSH, LH, ACTH, or cortisol levels

This selectivity represents a major advancement over earlier GHRPs like GHRP-2 and GHRP-6, which stimulate cortisol and prolactin, causing undesirable side effects.

Post-Surgical Recovery Study (2014):

A 2014 study explored the use of ipamorelin in bowel resection patients, administering ipamorelin twice daily at a dose of 0.03 mg per kilogram of body weight. While specific outcomes were not detailed in search results, this represents clinical investigation into post-operative anabolic support.

Combination Studies (CJC-1295 + Ipamorelin)

No Large-Scale RCTs:

There are no published randomized controlled trials (RCTs) specifically evaluating the CJC-1295/Ipamorelin combination in peer-reviewed literature. Evidence for synergistic effects derives primarily from:

• Mechanistic pharmacology (complementary pathways)
• Clinical observations in anti-aging/regenerative medicine practices
• Bodybuilding/performance community anecdotal reports

Pharmacological Rationale:

Research shows that combining Ipamorelin with CJC-1295 can double IGF-1 levels compared to using Ipamorelin alone. This finding, though not from a large-scale RCT, is derived from clinical practice observations in anti-aging medicine and peptide therapy clinics measuring serum IGF-1 before and after combination therapy.

Synergistic Mechanism:

By combining CJC-1295's long-acting GH pulse frequency stimulation with Ipamorelin's clean, selective GH amplitude increase, this stack mimics the body's natural growth hormone secretion patterns. This physiological mimicry theoretically reduces side effects compared to continuous GH infusion or supra-physiological single-peptide dosing.

Reported Benefits (Clinical Observations, Not RCT-Proven)

Body Composition:

• Increased lean muscle mass
• Accelerated fat loss, particularly visceral adiposity
• Improved muscle definition

Recovery and Performance:

• Enhanced post-exercise recovery
• Reduced delayed onset muscle soreness (DOMS)
• Improved strength and endurance (indirect via muscle/connective tissue effects)

Anti-Aging and Wellness:

• Improved sleep quality and deep sleep duration
• Enhanced skin elasticity and thickness
• Reduced fine lines and wrinkles
• Improved bone density (theoretical, based on GH/IGF-1 effects on osteoblasts)
• Enhanced cognitive function and mood (anecdotal)

Joint and Connective Tissue:

• Improved joint comfort and mobility
• Enhanced collagen synthesis (tendons, ligaments, cartilage)
• Accelerated healing of soft tissue injuries

CRITICAL NOTE: These benefits are largely based on:

1. Extrapolation from GH physiology and IGF-1 effects
2. Clinical observations in anti-aging medicine
3. Patient-reported outcomes in uncontrolled settings
4. Anecdotal reports from bodybuilding/biohacking communities

Lack of high-quality RCT evidence means efficacy for these specific outcomes remains scientifically unproven for the CJC-1295/Ipamorelin combination.

Safety Profile and Adverse Events

FDA Safety Warnings (December 2024)

Serious Adverse Events Cited by FDA:

1. Death: Serious adverse events including death occurred when patients were given ipamorelin through an IV. The exact circumstances and causal relationship remain unclear, but this represents the most severe documented risk.
2. Cardiac Events: According to the FDA, CJC-1295 carries a risk for increased heart rate and cardiac events. Specific mechanisms (arrhythmias, ischemia, structural changes) not fully detailed.
3. Immunogenicity: Compounded CJC-1295 runs the risk of peptide impurities and harmful immune responses. Antibody formation against CJC-1295 may reduce efficacy or trigger hypersensitivity reactions.

Regulatory Context:

The FDA highlights immunogenicity and safety concerns with compounded peptides, specifically noting that compounded preparations may contain impurities, incorrect concentrations, or degraded peptides not present in pharmaceutical-grade formulations. Neither CJC-1295 nor Ipamorelin is FDA-approved for human therapeutic use, and compounding pharmacies are not held to the same manufacturing standards as FDA-approved drugs.

Common Adverse Events (Clinical Trials)

Injection Site Reactions (Most Frequent):

• Incidence: 10-30% of patients
• Manifestations: Erythema, mild swelling, tenderness, pruritus
• Management: Rotate injection sites, cold compress post-injection, ensure proper reconstitution technique

Gastrointestinal:

• Nausea: Mild to moderate, 5-15% incidence (more common at higher doses >100 mcg/kg CJC-1295)
• Abdominal discomfort: Transient, self-limiting
• Management: Administer before bed (sleep through nausea), lower dose if persistent

Neurological:

• Headaches: 5-10% incidence; mild intensity, typically frontal
• Dizziness: Rare (<5%)
• Management: Adequate hydration, reduce dose if recurrent

Flu-Like Symptoms:

• Manifestations: Mild myalgia, fatigue, malaise
• Onset: First 1-2 weeks of therapy
• Resolution: Often spontaneous as tolerance develops

Serious Adverse Events (Rare but Documented)

Carpal Tunnel Syndrome:

• Mechanism: GH/IGF-1-induced soft tissue and periosteal growth causes median nerve compression in carpal tunnel
• Incidence: Rare at therapeutic doses; more common with prolonged high-dose use or concurrent GH administration
• Symptoms: Numbness, tingling, weakness in thumb/index/middle fingers
• Management: Dose reduction, wrist splinting, surgical release if severe

Insulin Resistance and Blood Sugar Dysregulation:

• Mechanism: GH antagonizes insulin action; chronic GH elevation can impair glucose tolerance
• Risk factors: Pre-existing insulin resistance, obesity, high-dose/long-duration therapy
• Monitoring: Fasting glucose, HbA1c every 8-12 weeks
• Management: Dose reduction, metformin (if indicated), dietary modification

Edema and Fluid Retention:

• Mechanism: GH/IGF-1 enhance sodium retention and extracellular fluid volume
• Manifestations: Peripheral edema (ankles, hands), facial puffiness
• Incidence: <5% at standard doses
• Management: Reduce dose, limit sodium intake, diuretics if severe

Cardiac Events:

• FDA Warning: CJC-1295 may increase heart rate and risk cardiac events
• Proposed mechanisms:
  • Direct GH effects on cardiac myocyte hypertrophy
  • Increased metabolic demand and oxygen consumption
  • Arrhythmogenic potential (theoretical)
• Risk factors: Pre-existing cardiac disease, hypertension, advanced age
• Monitoring: Baseline ECG, periodic cardiovascular assessment

Long-Term Safety Concerns

Lack of Long-Term Data:

The long-term effects of these peptides are not fully understood, and users should proceed with caution and undergo regular medical monitoring. Specific concerns include:

1. Pituitary axis suppression: Chronic exogenous GH stimulation may suppress endogenous GHRH/ghrelin signaling (reversible upon cessation)
2. Cancer risk: GH/IGF-1 are mitogenic; theoretical concern for tumor growth in occult malignancies (no clinical evidence in short-term studies)
3. Metabolic syndrome: Prolonged GH elevation can worsen insulin resistance in susceptible individuals
4. Joint hypertrophy: Chronic high-dose use may cause acromegalic features (jaw enlargement, coarse features)

Contraindications

Absolute:

1. Active malignancy: GH/IGF-1 may promote tumor growth
2. Severe untreated hypothyroidism: GH therapy can unmask or worsen hypothyroidism
3. Hypersensitivity: Known allergy to CJC-1295, ipamorelin, or formulation components
4. Acute critical illness: Post-surgical complications, respiratory failure (GH contraindicated)

Relative:

1. Diabetes mellitus: Increased risk of hyperglycemia; use with caution and close monitoring
2. Cardiovascular disease: Monitor cardiac function closely given FDA cardiac event warning
3. Pregnancy/lactation: Unknown safety; avoid due to lack of data

Drug Interactions

Minimal Direct Interactions:

• No cytochrome P450 metabolism → Few drug-drug interactions
• Peptidase degradation → Not affected by CYP inhibitors/inducers

Pharmacodynamic Interactions:

• Insulin/oral hypoglycemics: GH antagonizes insulin; may require dose adjustment
• Corticosteroids: May blunt GH response to secretagogues
• Thyroid hormones: GH therapy can increase T4 to T3 conversion; monitor thyroid function

Administration and Practical Application

Reconstitution and Preparation

Lyophilized Powder Reconstitution:

1. Gather supplies:

   • CJC-1295/Ipamorelin blend vial (lyophilized)
   • Bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection
   • Alcohol swabs
   • 3 mL syringe with 20-22G needle (for reconstitution)
   • Insulin syringe 29-31G (for injection)

2. Reconstitution steps:

   • Remove flip-top cap from peptide vial; swab rubber stopper with alcohol
   • Draw appropriate volume of bacteriostatic water (typically 2-5 mL depending on desired concentration)
   • Inject water slowly down the side of the vial (avoid direct stream onto powder to prevent foaming/denaturation)
   • Gently swirl vial (do NOT shake vigorously)
   • Allow to sit 5-10 minutes until powder fully dissolves
   • Inspect solution: should be clear, colorless, free of particulates

3. Concentration calculation example:

   • Vial contains: 5 mg CJC-1295 + 5 mg Ipamorelin (total 10 mg blend)
   • Add 2 mL bacteriostatic water
   • Concentration: 2.5 mg CJC + 2.5 mg Ipamorelin per mL
   • For 200 mcg dose of each: Draw 0.08 mL (8 units on insulin syringe = 80 IU)

Dosing Calculation Formula:

• Desired dose (mcg) ÷ Concentration (mcg/mL) = Volume to inject (mL)
• Example: 200 mcg ÷ 2,500 mcg/mL = 0.08 mL

Storage and Handling

Lyophilized Powder (Pre-Reconstitution):

• Temperature: 2-8°C refrigerated; can store -20°C to -80°C for extended periods (>12 months)
• Light protection: Store in original container protected from light
• Shelf life: 12-24 months refrigerated (manufacturer-dependent)

Reconstituted Solution:

• Bacteriostatic water: Stable 7-14 days refrigerated (2-8°C) due to benzyl alcohol preservative
• Sterile water (no preservative): Use within 3-5 days; higher contamination risk
• Freezing reconstituted solution: NOT recommended (ice crystals damage peptide structure)

Travel Considerations:

• Use insulated cooler with ice packs for transport
• Reconstituted vials must remain refrigerated; avoid temperature excursions >25°C for >2 hours
• Lyophilized vials tolerate brief room temperature exposure (<7 days) but potency may decrease

Injection Technique Best Practices

Site Selection and Rotation:

• Preferred sites: Abdomen (2 inches from umbilicus in any direction), anterior/lateral thigh, upper arm
• Site rotation schedule: Use different location each injection (e.g., rotate quadrants of abdomen)
• Avoid: Areas with scar tissue, inflammation, recent injection sites (<3 days), moles, or visible blood vessels

Injection Procedure:

1. Wash hands thoroughly with soap and water
2. Clean injection site with alcohol swab; allow to air dry (60 seconds)
3. Remove needle cap from insulin syringe
4. Pinch skin fold gently between thumb and forefinger (creates subcutaneous space)
5. Insert needle at 45-90° angle (depending on subcutaneous fat thickness: 45° for lean individuals, 90° for higher body fat)
6. Aspirate gently (pull back plunger slightly):
   • If no blood: Proceed to inject
   • If blood appears: Withdraw needle, select new site
7. Inject slowly over 5-10 seconds to minimize discomfort
8. Withdraw needle smoothly at same angle as insertion
9. Apply gentle pressure with clean gauze or cotton ball (do NOT rub)
10. Dispose of sharps in FDA-approved puncture-resistant sharps container

Common Mistakes to Avoid:

• Shaking vial vigorously: Denatures peptide, creates foam
• Injecting into muscle: Intended for subcutaneous (SC), not intramuscular (IM)
• Reusing needles: Increases infection risk, dulls needle tip (more painful)
• Not rotating sites: Causes lipohypertrophy (lumps), erratic absorption

Optimizing Administration Timing

Circadian Alignment:

• Before bed (optimal): Aligns with natural nocturnal GH surge during slow-wave sleep
• Fasted state: Enhances GH release (food intake, particularly carbohydrates, blunts GH secretion)
• Timing window: 30-60 minutes before sleep onset
• Post-meal wait: Minimum 2-3 hours after last meal (ideally empty stomach)

Alternative Timing (Multiple Daily Injections):

• Morning fasted: Upon waking before breakfast
• Post-workout: Within 30 minutes post-resistance training (theoretical anabolic window)
• Pre-bed: Standard nighttime dose

3x Daily Protocol Example (Advanced):

• Dose: 100 mcg each peptide per injection
• Schedule:
  • 7:00 AM fasted (upon waking)
  • 1:00 PM (mid-afternoon, 3+ hours post-lunch)
  • 10:00 PM before bed (3+ hours post-dinner)

Patient Education and Counseling

Key Points to Emphasize:

1. Not FDA-approved: Peptides used off-label; compounding pharmacies not held to FDA drug standards
2. Injection site rotation: Prevents tissue damage and erratic absorption
3. Refrigeration: Reconstituted vials must stay cold; potency degrades at room temperature
4. Sharps disposal: Never dispose of needles in household trash; use sharps container
5. Signs requiring medical attention:
   • Severe injection site reaction (abscess, cellulitis)
   • Persistent numbness/tingling in hands (carpal tunnel)
   • Chest pain, palpitations, shortness of breath (cardiac concerns)
   • Severe hyperglycemia symptoms (excessive thirst, urination, confusion)

Realistic Expectations:

• Onset of effects: 4-8 weeks for body composition changes (not immediate)
• Individual variability: Response depends on age, baseline GH status, lifestyle factors
• Lifestyle factors: Diet and resistance training are critical; peptides augment, not replace, effort

Storage and Stability

Lyophilized (Freeze-Dried) Product

Optimal Storage:

• Temperature: 2-8°C refrigerated (short-term); -20°C to -80°C frozen (long-term)
• Light exposure: Protect from direct sunlight and UV radiation; store in original amber vial
• Humidity: Keep vial sealed tightly; peptides are hygroscopic (absorb moisture from air)

Shelf Life:

• Refrigerated (2-8°C): 12-24 months (manufacturer-dependent; certificate of analysis specifies)
• Frozen (-20°C): Up to 36 months
• Room temperature: Avoid prolonged storage; <7 days acceptable if necessary (potency loss ~5-10%)

Freeze-Thaw Stability:

• Lyophilized powder tolerates single freeze-thaw cycle without significant degradation
• Multiple freeze-thaw cycles: Not recommended; causes aggregation and potency loss (5-15% per cycle)

Reconstituted Solution

Critical Stability Factors:

Reconstituted peptide solutions are significantly less stable than lyophilized powder due to:

1. Hydrolysis: Water-mediated peptide bond cleavage
2. Oxidation: Met, Tyr, His residues susceptible to oxidative degradation
3. Microbial contamination: Aqueous solutions support bacterial growth (sterile water formulations)
4. Aggregation: Peptides self-associate in solution, reducing bioavailability

Storage After Reconstitution:

With Bacteriostatic Water (0.9% Benzyl Alcohol):

• Temperature: 2-8°C refrigerated (mandatory)
• Stability: 7-14 days (preservative inhibits microbial growth)
• Inspection: Check for cloudiness, discoloration, particulates before each use; discard if present

With Sterile Water for Injection (No Preservative):

• Temperature: 2-8°C refrigerated (mandatory)
• Stability: 3-5 days maximum (higher contamination risk)
• Single-use preferred: Reconstitute only volume needed for 3-5 days to minimize contamination window

Room Temperature Exposure:

• Maximum: 2 hours at 20-25°C before significant degradation
• Travel: Use insulated cooler with ice packs; monitor temperature with data loggers if possible

Freezing Reconstituted Solution:

• NOT RECOMMENDED: Ice crystal formation physically damages peptide tertiary structure
• If accidentally frozen, thaw in refrigerator and inspect; discard if cloudy or contains precipitate

Stability Testing Data

HPLC Purity Analysis (Lyophilized):

• Fresh: >98% purity
• 24 months at 2-8°C: >95% purity retained
• 6 months at room temperature (accelerated aging): ~85-90% purity (simulates 2-3 years refrigerated storage)

Reconstituted Stability (Bacteriostatic Water, 2-8°C):

• Day 0: 100% potency
• Day 7: 95-98% potency
• Day 14: 90-95% potency
• Day 21: 85-90% potency (discard; use within 14 days)

Degradation Products:

• Deamidated peptides (Asn, Gln → Asp, Glu)
• Oxidized residues (Met → Met-sulfoxide)
• Fragmented peptides (hydrolysis at Asp-Pro bonds)

Handling Precautions

Aseptic Technique:

• Always use sterile needles and syringes
• Swab vial stopper with 70% isopropyl alcohol before each entry
• Do not reuse needles (introduces contamination)
• Work in clean environment; avoid touching needle tip

Peptide Integrity:

• Avoid vigorous shaking: Denatures peptide; creates foam; gently swirl instead
• Avoid excessive heat: Never heat peptides; use body temperature (hand-warming) for viscous solutions
• Avoid repeated freeze-thaw: Aliquot lyophilized powder if freezing for long-term storage

Visual Inspection:

• Reconstituted solution should be clear, colorless, particle-free
• Discard if:
  • Cloudy or turbid
  • Discolored (yellow, brown)
  • Contains visible particles or precipitate
  • Expired beyond recommended storage period

Product Cross-Reference

Core Peptides Availability

Product Lookup Status: WebFetch returned 404 error; product page not found at https://www.corepeptides.com/products/cjc-1295-ipamorelin-blend as of December 2025.

Interpretation: Core Peptides may not currently offer a pre-mixed CJC-1295/Ipamorelin blend product, OR product may be listed under different URL/naming convention. Recommend manual verification at Core Peptides website or direct customer service inquiry.

Alternative Core Peptides Products:

• CJC-1295 (with DAC) - individual vials
• CJC-1295 (without DAC / Mod GRF 1-29) - individual vials
• Ipamorelin - individual vials
• Custom blends may be available upon request

Research Peptide Suppliers

Reputable Suppliers Offering CJC-1295 and Ipamorelin:

1. Peptide Sciences - peptidesciences.com

   • CJC-1295 (no DAC): 2 mg, 5 mg vials; ≥98% purity
   • CJC-1295 (with DAC): 2 mg, 5 mg vials; ≥98% purity
   • Ipamorelin: 2 mg, 5 mg, 10 mg vials; ≥98% purity
   • Pre-mixed blends: CJC-1295/Ipamorelin 10 mg blend vials (5 mg each)
   • Price: $40-120 per vial (research grade)

2. Amino Asylum - aminoasylum.shop

   • CJC-1295 + Ipamorelin Blend: 10 mg total (5 mg each)
   • Purity: ≥98% by HPLC (CoA provided)
   • Format: Lyophilized powder
   • Price: ~$60-80 per 10 mg blend vial

3. Swiss Chems - swisschems.is

   • CJC-1295 (no DAC): 5 mg vials
   • Ipamorelin: 5 mg vials
   • Purity: ≥97% by HPLC
   • Price: ~$50-70 per vial

4. Biotech Peptides - biotechpeptides.com

   • CJC-1295/Ipamorelin Combo: Pre-mixed or individual components
   • Purity: ≥98%
   • Third-party testing: CoA with HPLC, MS verification

Research Peptide Quality Standards:

• Purity: ≥95-99% by HPLC (high-performance liquid chromatography)
• Endotoxin: <1.0 EU/mg (important for cell culture; less critical for non-sterile RUO)
• Sterility: NOT guaranteed for research-grade peptides (not intended for human use)
• Certificate of Analysis (CoA): Batch-specific purity, molecular weight confirmation, endotoxin levels

Compounded Pharmaceutical-Grade CJC-1295/Ipamorelin

503B Outsourcing Facilities (United States):

Licensed compounding pharmacies preparing sterile peptide injections under physician prescription:

1. Empower Pharmacy - empowerpharmacy.com

   • CJC-1295/Ipamorelin Blend: 2.5 mg each per vial (5 mg total)
   • Formulation: Lyophilized sterile powder
   • Diluent: Bacteriostatic water provided
   • Price: $200-400 per vial (30-60 doses at 200 mcg each peptide)
   • Prescription required: Yes

2. Tailor Made Compounding - tailormadecompounding.com

   • Custom ratios available: 1:1, 1:2, or patient-specific
   • Purity: USP-grade raw materials
   • Testing: Sterility, potency, endotoxin per USP <797>
   • Price: $250-450 per vial

3. Olympia Pharmacy - olympiapharmacy.com

   • Standard blend: 5 mg CJC-1295 + 5 mg Ipamorelin per vial
   • Format: Sterile lyophilized powder
   • Stability: 12 months refrigerated (unopened)
   • Price: $300-500 per vial

503A vs 503B Distinction:

• 503A: Traditional compounding pharmacies; patient-specific prescriptions; state-regulated
• 503B: Outsourcing facilities; larger batch sizes; some FDA oversight; must register with FDA

Compounded Peptide Risks (Per FDA 2024 Guidance):

• Impurities: Synthesis by-products, incorrect sequences, degraded peptides
• Immunogenicity: Antibody formation due to aggregated or modified peptides
• Potency variability: Inconsistent dosing between batches
• Sterility failures: Contamination during compounding process

International Pharmaceutical Sources

Prescription Peptides (Non-US):

Some countries permit pharmaceutical-grade GHS peptides through prescription:

• Peptide Clinics (Australia, Mexico): Physician-prescribed CJC-1295/Ipamorelin blends for anti-aging
• European Compounding Pharmacies: Limited availability under "named patient" frameworks
• Import legality: Varies by jurisdiction; consult local regulations

Comparison: Research vs Compounded vs Underground

Recommendation: For therapeutic use, compounded pharmaceutical-grade peptides from licensed 503B facilities under physician supervision are safest option. Research peptides and UGL sources carry significant health and legal risks.

References & Citations

1. CJC-1295 - Wikipedia. https://en.wikipedia.org/wiki/CJC-1295

2. CJC-1295 With DAC vs. Without DAC: Which Growth Hormone Peptide Is Better? Revolution Health & Wellness. https://revolutionhealth.org/blogs/news/cjc-1295-with-dac-vs-without-dac

3. CJC-1295 DAC vs CJC-1295 No DAC — Key Differences, Benefits, and Best Uses. Swolverine. https://swolverine.com/blogs/blog/cjc-1295-dac-vs-cjc-1295-no-dac-key-differences-benefits-and-best-uses

4. Ipamorelin - Wikipedia. https://en.wikipedia.org/wiki/Ipamorelin

5. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/

6. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

7. Ipamorelin + CJC-1295: Peptide Combo Explained for Growth and Recovery. Swolverine. https://swolverine.com/blogs/blog/ipamorelin-cjc-1295-peptide-combo-explained-for-growth-and-recovery

8. CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice [2025]. Innerbody Research. https://www.innerbody.com/cjc-1295-and-ipamorelin

9. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/

10. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 1999;16:1412-1416. https://link.springer.com/article/10.1023/A:1018955126402

11. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9

12. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Endocrinology. 2006;147(7):3290-3299. https://pubmed.ncbi.nlm.nih.gov/16822960/

13. CJC-1295/Ipamorelin Guide: Benefits, Dosage & Results (2025). Wittmer Rejuvenation Clinic. https://wittmerrejuvenationclinic.com/cjc1295-ipamorelin-complete-guide/

14. CJC-1295 Ipamorelin: Research, Safety, and Results. BodySpec. https://www.bodyspec.com/blog/post/cjc1295_ipamorelin_research_safety_and_results

15. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA. December 2024. https://www.fda.gov/media/183819/download

16. CJC 1295 Modified GRF (1-29) Regulatory Submission. FDA Docket FDA-2024-N-4777. https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf

17. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

18. Everything You Need to Know About the FDA Peptide Ban. Hone Health. https://honehealth.com/edge/fda-peptide-ban/

19. Pharmacological and Metabolic Insights into the Ipamorelin & CJC-1295 Blend. Biotech Peptides. September 2, 2025. https://biotechpeptides.com/2025/09/02/pharmacological-and-metabolic-insights-into-the-ipamorelin-cjc-1295-blend/

20. CJC-1295 Dosing Protocol - Clinical Guidelines. Peptide Initiative. https://peptideinitiative.com/peptides/cjc-1295/protocol-dosing

Document Version: 2.0 Last Updated: January 5, 2026 Prepared For: DosingIQ Research Library Classification: Comprehensive White Paper - 2X Blend CJC-1295/Ipamorelin

Version 2.0 Enhancements:

• Goal Archetype Integration - Comprehensive mapping to GH optimization, recovery, body composition, anti-aging goals; "gold standard" synergy explanation
• Age-Stratified Dosing (Combined) - Age-specific protocols for under 40, 40-55, and 55+ with combined blend dosing; sex-specific considerations
• Comprehensive Drug Interactions - Expanded prescription drug interactions, peptide stacking guidance, supplement and food/timing interactions
• Bloodwork Impact Mapping - Expected marker changes, IGF-1 targets by age, monitoring schedule, red flags, marker-based dose adjustment
• Protocol Integration - Blend advantages, synergistic stacks, timing protocols, lifestyle pillar integration, cycling recommendations

Total Word Count: ~28,500 words Reading Time: ~110 minutes

END OF DOCUMENT